AU2017367722B2 - Tau modulators and methods and compositions for delivery thereof - Google Patents
Tau modulators and methods and compositions for delivery thereof Download PDFInfo
- Publication number
- AU2017367722B2 AU2017367722B2 AU2017367722A AU2017367722A AU2017367722B2 AU 2017367722 B2 AU2017367722 B2 AU 2017367722B2 AU 2017367722 A AU2017367722 A AU 2017367722A AU 2017367722 A AU2017367722 A AU 2017367722A AU 2017367722 B2 AU2017367722 B2 AU 2017367722B2
- Authority
- AU
- Australia
- Prior art keywords
- tau
- mapt
- normalized expression
- abc
- zfp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428871P | 2016-12-01 | 2016-12-01 | |
| US62/428,871 | 2016-12-01 | ||
| US201762450895P | 2017-01-26 | 2017-01-26 | |
| US62/450,895 | 2017-01-26 | ||
| US201762466198P | 2017-03-02 | 2017-03-02 | |
| US62/466,198 | 2017-03-02 | ||
| US201762500807P | 2017-05-03 | 2017-05-03 | |
| US62/500,807 | 2017-05-03 | ||
| US201762584342P | 2017-11-10 | 2017-11-10 | |
| US62/584,342 | 2017-11-10 | ||
| PCT/US2017/064181 WO2018102665A1 (en) | 2016-12-01 | 2017-12-01 | Tau modulators and methods and compositions for delivery thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2017367722A1 AU2017367722A1 (en) | 2019-05-30 |
| AU2017367722A8 AU2017367722A8 (en) | 2019-06-13 |
| AU2017367722B2 true AU2017367722B2 (en) | 2024-02-01 |
Family
ID=62239970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017367722A Active AU2017367722B2 (en) | 2016-12-01 | 2017-12-01 | Tau modulators and methods and compositions for delivery thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11504389B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3548616A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7292204B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102674612B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110214184B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017367722B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3043635A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL266862B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019006426A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018102665A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210069692A (ko) * | 2018-10-02 | 2021-06-11 | 상가모 테라퓨틱스, 인코포레이티드 | 조작된 유전자 조정제 |
| IL326834A (en) | 2018-10-02 | 2026-04-01 | Sangamo Therapeutics Inc | Artificial zinc finger protein transcription factors repressing mapt expression for the prevention and/or treatment of tauopathies |
| EA202192801A1 (ru) * | 2019-04-12 | 2022-02-24 | Инкоудид Терапьютикс, Инк. | Композиции и способы введения лекарственных средств |
| JP7618581B2 (ja) | 2019-04-23 | 2025-01-21 | サンガモ セラピューティクス, インコーポレイテッド | 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 |
| WO2021067871A1 (en) * | 2019-10-02 | 2021-04-08 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for repressing alpha-synuclein expression |
| US20230020565A1 (en) | 2019-12-04 | 2023-01-19 | Sangamo Therapeutics, Inc. | Novel compositions and methods for producing recombinant aav |
| TW202134288A (zh) * | 2020-01-22 | 2021-09-16 | 美商聖加莫治療股份有限公司 | 用於抑制tau蛋白表現之鋅指蛋白轉錄因子 |
| WO2022009987A1 (en) * | 2020-07-09 | 2022-01-13 | Modalis Therapeutics Corporation | Method for treating alzheimer's disease by targeting mapt gene |
| CN112640847B (zh) * | 2020-12-30 | 2022-12-13 | 重庆医科大学附属第一医院 | 一种内源性癫痫发作动物模型及其构建方法 |
| WO2025193848A1 (en) * | 2024-03-13 | 2025-09-18 | Sangamo Therapeutics, Inc. | Delivery of tau repressors using the blood-brain barrier penetrant capsid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015153760A2 (en) * | 2014-04-01 | 2015-10-08 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a nervous system disorder |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| JP4012243B2 (ja) | 1994-01-18 | 2007-11-21 | ザ スクリップス リサーチ インスティチュート | 亜鉛フィンガータンパク質誘導体およびそのための方法 |
| CA2186118C (en) | 1994-03-23 | 2010-10-19 | Richard W. Hanson | Compacted nucleic acids and their delivery to cells |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| CA2196419C (en) | 1994-08-20 | 2007-08-21 | Yen Choo | Improvements in or relating to binding proteins for recognition of dna |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| DE69942334D1 (de) | 1998-03-02 | 2010-06-17 | Massachusetts Inst Technology | Poly-zinkfinger-proteine mit verbesserten linkern |
| CA2329259C (en) | 1998-05-27 | 2003-08-05 | Avigen, Inc. | Convection-enhanced delivery of aav vectors |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6503717B2 (en) | 1999-12-06 | 2003-01-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| AU2001250774B2 (en) | 2000-02-08 | 2005-01-27 | Sangamo Biosciences, Inc. | Cells expressing zinc finger proteins for drug discovery |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| WO2002046412A2 (en) | 2000-12-07 | 2002-06-13 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| US7182944B2 (en) | 2001-04-25 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of increasing distribution of nucleic acids |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| EP1463805B1 (en) | 2001-12-17 | 2014-10-22 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| WO2005004794A2 (en) * | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| CN1856573A (zh) * | 2003-09-25 | 2006-11-01 | 千叶县政府 | 用于神经母细胞瘤预后诊断的微阵列和神经母细胞瘤预后诊断方法 |
| CN1897977A (zh) | 2003-10-20 | 2007-01-17 | Ns基因公司 | 帕金森氏病的体内基因治疗 |
| WO2006042090A1 (en) | 2004-10-05 | 2006-04-20 | Avigen, Inc. | Stepped cannula |
| WO2006121866A2 (en) | 2005-05-05 | 2006-11-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
| JP5238503B2 (ja) | 2005-08-23 | 2013-07-17 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 対流増加送達を用いた治療薬の慢性的な送達のための逆流防止カニューレ及びシステム |
| SI2019683T2 (sl) | 2006-04-25 | 2022-10-28 | The Regents Of The University Of California | Dajanje rastnih faktorjev za zdravljenje motenj CŽS |
| EP2027262B1 (en) | 2006-05-25 | 2010-03-31 | Sangamo Biosciences Inc. | Variant foki cleavage half-domains |
| US7837668B2 (en) | 2006-10-10 | 2010-11-23 | Ceregene, Inc. | Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of same |
| US8153773B2 (en) | 2007-06-19 | 2012-04-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
| JP5763341B2 (ja) | 2007-09-27 | 2015-08-12 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 生物学的活性のあるヌクレアーゼの迅速なインビボ同定法 |
| JP5763530B2 (ja) | 2008-06-10 | 2015-08-12 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Bax−およびBak−欠損細胞株の生成のための方法および組成物 |
| JP5908725B2 (ja) | 2008-08-22 | 2016-04-26 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 標的一本鎖開裂および標的組込みのための方法、並びに組成物 |
| US20110023153A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in alzheimer's disease |
| US20110016539A1 (en) | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of neurotransmission-related genes in animals |
| KR20100080068A (ko) * | 2008-12-31 | 2010-07-08 | 주식회사 툴젠 | 신규한 징크 핑거 뉴클레아제 및 이의 용도 |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| CA2769262C (en) | 2009-07-28 | 2019-04-30 | Sangamo Biosciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
| EA022786B1 (ru) | 2009-07-31 | 2016-03-31 | Этрис Гмбх | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US20110135613A1 (en) * | 2009-12-03 | 2011-06-09 | The J. David Gladstone Institutes | Methods for treating apolipoprotein e4-associated disorders |
| JP6137596B2 (ja) | 2010-02-08 | 2017-05-31 | サンガモ セラピューティクス, インコーポレイテッド | 遺伝子操作された切断ハーフドメイン |
| EP2566972B1 (en) | 2010-05-03 | 2020-01-15 | Sangamo Therapeutics, Inc. | Compositions for linking zinc finger modules |
| AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
| US9322023B2 (en) | 2011-10-06 | 2016-04-26 | Cornell University | Constructs and methods for the assembly of biological pathways |
| WO2013074999A1 (en) | 2011-11-16 | 2013-05-23 | Sangamo Biosciences, Inc. | Modified dna-binding proteins and uses thereof |
| CA2865011C (en) | 2012-02-29 | 2021-06-15 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
| EP2931899A1 (en) * | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| BR112015022156A2 (pt) * | 2013-03-14 | 2017-11-14 | Isis Pharmaceuticals Inc | composições e métodos para modular a expressão de tau |
| EP2997146A4 (en) | 2013-05-15 | 2017-04-26 | Sangamo BioSciences, Inc. | Methods and compositions for treatment of a genetic condition |
| WO2014197748A2 (en) | 2013-06-05 | 2014-12-11 | Duke University | Rna-guided gene editing and gene regulation |
| TWI702046B (zh) * | 2013-07-19 | 2020-08-21 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| US9359599B2 (en) * | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| JP2017505756A (ja) * | 2013-12-13 | 2017-02-23 | ザ ジェネラル ホスピタル コーポレイション | 可溶性高分子量(hmw)タウ種およびその用途 |
| EP3929279A1 (en) | 2014-03-18 | 2021-12-29 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of zinc finger protein expression |
| BR112016025849A2 (pt) | 2014-05-08 | 2017-10-17 | Chdi Foundation Inc | métodos e composições para o tratamento da doença de huntington |
| US9970001B2 (en) * | 2014-06-05 | 2018-05-15 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease design |
| CA2975525A1 (en) * | 2015-02-04 | 2016-08-11 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
| US20170035860A1 (en) * | 2015-04-02 | 2017-02-09 | Alexander C. Flynn | Compositions and methods for treatment of neurogenerative diseases |
| WO2017011556A1 (en) | 2015-07-13 | 2017-01-19 | The General Hospital Corporation | Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof |
| US10143760B2 (en) | 2015-10-28 | 2018-12-04 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
| WO2017197141A2 (en) | 2016-05-13 | 2017-11-16 | Sangamo Therapeutics, Inc. | Targeted treatment of androgenic alopecia |
| WO2018039440A1 (en) * | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
| IL264792B2 (en) | 2016-08-24 | 2023-10-01 | Sangamo Therapeutics Inc | Engineered target-specific zinc-finger nucleases |
| WO2018039471A2 (en) | 2016-08-25 | 2018-03-01 | Trustees Of Boston University | Synthetic transcriptional and epigenetic regulators based on engineered, orthogonal zinc finger proteins |
| JP7256739B2 (ja) | 2016-09-07 | 2023-04-12 | サンガモ セラピューティクス, インコーポレイテッド | 肝臓遺伝子のモジュレーション |
| US11371023B2 (en) | 2016-11-22 | 2022-06-28 | Wisconsin Alumni Research Foundation | Artificial transcription factors and uses thereof |
| IL326834A (en) | 2018-10-02 | 2026-04-01 | Sangamo Therapeutics Inc | Artificial zinc finger protein transcription factors repressing mapt expression for the prevention and/or treatment of tauopathies |
| KR20210069692A (ko) | 2018-10-02 | 2021-06-11 | 상가모 테라퓨틱스, 인코포레이티드 | 조작된 유전자 조정제 |
| TW202134288A (zh) | 2020-01-22 | 2021-09-16 | 美商聖加莫治療股份有限公司 | 用於抑制tau蛋白表現之鋅指蛋白轉錄因子 |
-
2017
- 2017-12-01 CN CN201780084345.1A patent/CN110214184B/zh active Active
- 2017-12-01 US US15/828,931 patent/US11504389B2/en active Active
- 2017-12-01 AU AU2017367722A patent/AU2017367722B2/en active Active
- 2017-12-01 IL IL266862A patent/IL266862B2/en unknown
- 2017-12-01 WO PCT/US2017/064181 patent/WO2018102665A1/en not_active Ceased
- 2017-12-01 EP EP17876620.0A patent/EP3548616A4/en active Pending
- 2017-12-01 MX MX2019006426A patent/MX2019006426A/es unknown
- 2017-12-01 KR KR1020197016870A patent/KR102674612B1/ko active Active
- 2017-12-01 JP JP2019529263A patent/JP7292204B2/ja active Active
- 2017-12-01 CA CA3043635A patent/CA3043635A1/en active Pending
-
2022
- 2022-10-13 US US18/046,327 patent/US20230270774A1/en active Pending
-
2023
- 2023-03-29 JP JP2023053704A patent/JP2023078446A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015153760A2 (en) * | 2014-04-01 | 2015-10-08 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a nervous system disorder |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110214184B (zh) | 2024-07-02 |
| RU2019120040A (ru) | 2021-01-11 |
| EP3548616A1 (en) | 2019-10-09 |
| WO2018102665A1 (en) | 2018-06-07 |
| IL266862A (en) | 2019-07-31 |
| IL266862B1 (en) | 2023-09-01 |
| IL266862B2 (en) | 2024-01-01 |
| EP3548616A4 (en) | 2020-05-13 |
| JP2020500526A (ja) | 2020-01-16 |
| JP7292204B2 (ja) | 2023-06-16 |
| CN110214184A (zh) | 2019-09-06 |
| MX2019006426A (es) | 2019-08-14 |
| RU2019120040A3 (cg-RX-API-DMAC7.html) | 2021-04-09 |
| JP2023078446A (ja) | 2023-06-06 |
| AU2017367722A8 (en) | 2019-06-13 |
| US11504389B2 (en) | 2022-11-22 |
| US20180153921A1 (en) | 2018-06-07 |
| CA3043635A1 (en) | 2018-06-07 |
| BR112019010014A2 (pt) | 2019-08-20 |
| KR102674612B1 (ko) | 2024-06-14 |
| KR20190085529A (ko) | 2019-07-18 |
| AU2017367722A1 (en) | 2019-05-30 |
| US20230270774A1 (en) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250099624A1 (en) | Methods and compositions for the treatment of rare diseases | |
| US20250313848A1 (en) | Engineered genetic modulators | |
| US20230270774A1 (en) | Tau modulators and methods and compositions for delivery thereof | |
| US20250268981A1 (en) | Methods and compositions for modulation of tau proteins | |
| RU2789459C2 (ru) | Модуляторы тау и способы и композиции для их доставки |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 33 , NO 20 , PAGE(S) 2979 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME THE GENERAL HOSPITAL CORPORATION, APPLICATION NO. 2017367722, UNDER INID (71) ADD CO-APPLICANT SANGAMO THERAPEUTICS, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |